Earnings
United Therapeutics Slips Soft Mist Inhaler Filing Into 2027 After FDA Meeting
The company is also "treading water" on a triple-combination drug, and its oral ralinepag supplier carries a compliance flag.
United Therapeutics (UTHR) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
The company is also "treading water" on a triple-combination drug, and its oral ralinepag supplier carries a compliance flag.
Earnings
Revenue rose 4% to $832.5 million, but a Thymmune-related research cost and a higher tax rate cut earnings, and the board approved a $2.0 billion buyback.
Earnings
The lump sum to Pfizer's Arena unit hits fourth-quarter R&D expense, while the FDA's June 24, 2027 goal date for ralinepag hangs on a supplier fix.
Insider Trades
The CEO's next planned sale is 119,410 shares, on top of 608,000 shares already sold for $319,182,640 under a pre-set trading plan.
SEC Filings
The new program runs through October 21, 2027 and sets no minimum purchase, while a September accelerated repurchase continues.
SEC Filings
The 8-K says $185 million is due within 30 business days, with $145.4 million to follow in two installments.